Tier 4 — mechanistic

Ingestion of BioCell Collagen®, a novel hydrolyzed chicken sternal cartilage extract; enhanced blood microcirculation and reduced facial aging signs

Stephen R Schwartz, Joosang Park
Clinical Interventions in Aging 2012 7:267-273

Bibliography

PubMed
PMID 22956862
PubMed Central
PMC3426261
DOI
10.2147/CIA.S32836
Funding
Funded by BioCell Technology LLC; study supplement provided by GMP Laboratories of America.
Competing interests
Joosang Park was an employee of BioCell Technology LLC at manuscript submission; Stephen R Schwartz reported no financial interest.

Study snapshot

DesignOpen-label pilot study
ModelHealthy women with visible facial photoaging
Samplen=26
InterventionBioCell Collagen 1 g/day containing hydrolyzed type II collagen, low-molecular-weight HA and chondroitin sulfate
Duration12 weeks
EndpointsSkin dryness/scaling; Lines and wrinkles; Dermal hemoglobin; Dermal collagen

What the study showed, in plain terms

This uncontrolled 12-week pilot found improvements in dryness/scaling, facial lines and some dermal measures after BioCell Collagen supplementation. It is included because the product contains low-molecular-weight HA, but the absence of placebo and the collagen/chondroitin matrix mean the results cannot be attributed to HA alone.

Key findings

What this study can and cannot tell us

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology